Celiac Disease and Gluten-Free Diet Support
- Questions? Join our forum: Nearly 1 MILLION POSTS, and over 62,000 MEMBERS!
Follow / Share
|Get Email Alerts|
- Safe Gluten-Free Food List (Safe Ingredients)
- Unsafe Gluten-Free Food List (Unsafe Ingredients)
- Gluten-Free Alcoholic Beverages
- Celiac Disease Symptoms
- The Gluten-Free Diet 101 - A Beginner's Guide to Going Gluten-Free
- Interpretation of Celiac Disease Blood Test Results
- Is Buckwheat Flour Really Gluten-Free?
Cancer, Lymphoma and Celiac Disease
The nature of gut intraepithelial lymphocytes (IELs) lacking antigen receptors remains controversial. A team of researchers recently set out to better understand the mechanisms by which innate intraepithelial lymphocytes develop in the intestine and become cancerous in celiac disease patients.
A new understanding of CD30 expression in EATL may lead to better therapies using anti-CD30 monoclonal antibodies, like brentuximab vedotin (BV).
A new study reveals that U.S. Asians experience higher rates of deadlier cases of Enteropathy-associated T-cell lymphoma EATL.
The connection between celiac disease and various types of cancer is well supported by scientific evidence. However, to date, there hasn’t been enough data to make accurate predictions of cancer risk in celiac patients. So, we don’t know exactly what the risk levels are for various types of cancer in celiac patients.
Researchers wanted to identify the predictors of celiac disease in patients presenting with D-IEL.
To determine which method yielded better diagnostic results, a research team set out to compare and contrast intestinal intraepithelial lymphocyte cytometric pattern with subepithelial deposits of anti-tissue transglutaminase IgA for diagnosing lymphocytic enteritis due to celiac disease.
People with celiac disease have higher rates of lymphoproliferative malignancy. Currently, doctors just don't know whether risk levels are affected by the results of follow-up intestinal biopsy, performed to document mucosal healing.
Enteropathy-associated T cell lymphoma (EATL) is a gut cancer that often ends in death. Currently, doctors have very little idea what factors might help patients survive. The way in which clinical presentation, pathological features and therapies influence EATL outcome was the subject of a recent study by a team of researchers.
Currently, there is no cure for T-cell lymphoma, and no promising treatment exists for people who suffer from this condition. However, results of a new study suggest that new treatments for T-cell lymphoma my be on the horizon.
With all the problems that go along with celiac disease, it can be hard to see any benefits to having the disease. However, it would seem that such benefits do exist: a recent study in Sweden shows that women suffering from celiac disease are actually at a decreased risk of developing breast, endometrial and ovarian cancer.
A number of studies have found higher rates of lymphoma in people with celiac disease. However, few studies make any distinction between lymphoproliferative disorders (LPDs). A team of researchers recently investigated rates of various lymphoproliferative disorders in patients with celiac disease.
A team of researchers recently set out to map the IL-15–driven survival pathway in human IELs, and to determine whether IL-15 triggered pathway in human intraepithelial lymphocytes represents a possible new target in type II refractory celiac disease and enteropathy-associated T cell lymphoma.